Literature DB >> 19135977

Inhibition of vascular endothelial growth factor expression by TRUE gene silencing.

Reyad A Elbarbary1, Hiroaki Takaku, Masato Tamura, Masayuki Nashimoto.   

Abstract

Pathogenic angiogenesis in various diseases including cancer, autoimmune diseases, and age-related macular degeneration is thought to be regressed with anti-angiogenic drugs. TRUE gene silencing is a new technology to eliminate a specific mRNA using synthetic sgRNA and cellular tRNase Z(L). To discover anti-angiogenic sgRNAs, we applied TRUE silencing to the VEGF gene. We examined eight sgRNAs for efficacy in targeting exogenous human VEGF mRNA. Many of them worked efficiently in 293 and HeLa cells. Two of them downregulated the endogenous VEGF gene expression in HeLa cells very efficiently, and the efficacy of these two sgRNAs surpassed that of siRNA extremely.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19135977     DOI: 10.1016/j.bbrc.2008.12.173

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

Review 1.  TRUE Gene Silencing.

Authors:  Masayuki Nashimoto
Journal:  Int J Mol Sci       Date:  2022-05-11       Impact factor: 6.208

2.  TRUE Gene Silencing: Screening of a Heptamer-type Small Guide RNA Library for Potential Cancer Therapeutic Agents.

Authors:  Arisa Haino; Tatsuya Ishikawa; Mineaki Seki; Masayuki Nashimoto
Journal:  J Vis Exp       Date:  2016-06-02       Impact factor: 1.355

3.  Elimination of specific miRNAs by naked 14-nt sgRNAs.

Authors:  Masayuki Takahashi; Reyad A Elbarbary; Mayumi Abe; Mari Sato; Tetsuo Yoshida; Yoji Yamada; Masato Tamura; Masayuki Nashimoto
Journal:  PLoS One       Date:  2012-06-04       Impact factor: 3.240

4.  Growth inhibition of head and neck squamous cell carcinoma cells by sgRNA targeting the cyclin D1 mRNA based on TRUE gene silencing.

Authors:  Satoshi Iizuka; Nobuhiko Oridate; Masayuki Nashimoto; Satoshi Fukuda; Masato Tamura
Journal:  PLoS One       Date:  2014-12-01       Impact factor: 3.240

5.  Potential small guide RNAs for tRNase ZL from human plasma, peripheral blood mononuclear cells, and cultured cell lines.

Authors:  Sho Ninomiya; Mitsuoki Kawano; Takashi Abe; Tatsuya Ishikawa; Masayuki Takahashi; Masato Tamura; Yoshiaki Takahashi; Masayuki Nashimoto
Journal:  PLoS One       Date:  2015-03-02       Impact factor: 3.240

6.  The Y4-RNA fragment, a potential diagnostic marker, exists in saliva.

Authors:  Tatsuya Ishikawa; Arisa Haino; Mineaki Seki; Hiroshi Terada; Masayuki Nashimoto
Journal:  Noncoding RNA Res       Date:  2017-07-26

7.  The heptamer sgRNA targeting the human OCT4 mRNA can upregulate the OCT4 expression.

Authors:  Tadasuke Nozaki; Masayuki Takahashi; Tatsuya Ishikawa; Arisa Haino; Mineaki Seki; Hidetomo Kikuchi; Bo Yuan; Masayuki Nashimoto
Journal:  Biochem Biophys Rep       Date:  2021-02-02

8.  Modulation of gene expression by human cytosolic tRNase Z(L) through 5'-half-tRNA.

Authors:  Reyad A Elbarbary; Hiroaki Takaku; Naoto Uchiumi; Hiroko Tamiya; Mayumi Abe; Masayuki Takahashi; Hiroshi Nishida; Masayuki Nashimoto
Journal:  PLoS One       Date:  2009-06-15       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.